Skip to content

Month: January 2024

Published on Leave a comment on Seeing Spots Before Your Eyes?

Washington, DC, had a record high temperature 1 day during our heat wave this past week, and I suppose if you glanced at the sun you might see some spots for a few seconds. But of course I'm referring to different spots in this post.

Measles

I'm probably the only person who has read all of my blog posts over time, so you're forgiven if you don't realize I'm in broken record mode here. I can't count the number of times I've warned providers to be on the lookout for measles cases, and now we are facing a global decline in immunization rates that probably puts us at greatest risk since the modern-day measles vaccine was available in 1968 (the original Enders vaccine appeared in 1963). We've enjoyed some low numbers in the US recently, but that appears to be changing with 9 cases (from Georgia, Missouri, New Jersey, and Pennsylvania) reported to CDC so far this month.

CDC released an alert last week mentioning 23 US cases between December 1 and January 23.

I won't review everything about diagnosis of measles, the CDC website alert is a good resource with links to other sites, but I do want to highlight a few helpful nuances that aren't often mentioned. First, measles is fairly unique among exanthematous infections in that the prodrome interval, the time between onset of first symptoms and appearance of the rash, is long, usually a few days. Most infectious diseases accompanied by rash have very little or no time between onset of symptoms and appearance of the rash, with erythema infectiosum being a notable exception but not easily confused with measles clinically.

The measles prodrome consists of a febrile illness with cough, coryza, conjunctivitis, and Koplik's spots. You can find pictures of Koplik's spots everywhere on the web, but in my experience as an old geezer who has seen many cases of measles in children, they aren't that easy to see or photograph. Therefore, the photos available in textbooks and on line are skewed towards the most obvious. One needs to do a careful oral exam looking for gray or bluish-gray or white fine spots (almost sandpapery) anywhere on the buccal mucosa; the inside of the lower lip is particularly helpful. If you're not sure, find an old geezer clinician to confirm.

In the absence of Koplik spots, or if you don't see the child until the rash appears and the Koplik spots have resolved, pay close attention to the history. Specifically ask for a day-to-day accounting of symptoms; if you feel the parent or patient can recall reliably, noting at least a 2-3 day lag between the onset of high fever, cough, rhinorrhea, and conjunctivitis before the rash appears can be strongly suggestive of measles; the absence of this lag is against the diagnosis. Other alarms to increase your suspicion would be lack of 2 measles immunizations, international travel, and/or exposure to a suspected measles case.

"It ain't what they call you.....

..... it's what you answer to." - attributed to W.C. Fields, though I can't verify the origin.

I thought of Mr. Fields when I heard about administration errors involving the adult RSV vaccine (brand names Abrysvo and Arexvy) given to children and pregnant people. From my viewpoint, it was an accident waiting to happen, due to a name.

In order to speed payment allowance by the Vaccines for Children and other programs, the long-acting monoclonal antibody nirsevimab was officially designated a vaccine. Strictly speaking I guess this is correct: antibody administration is a form of passive immunization. However, the true RSV vaccines are intended only for adults with high risk conditions or for pregnant people to help protect newborns after birth. It was inevitable that confusion would ensue. The notice provides almost no details but does state that most administrations to young infants were "nonserious." Infants who wrongly received an adult RSV vaccine should be considered unprotected and still receive nirsevimab.

WHO Fans the Covid Mask/Distancing Controversy

WHO riled a lot of public health experts with its recent guidance for infection control in healthcare facilities. The main controversial elements involve recommendations to use physical barriers such as plastic windows for areas where patients first present (rated as conditional recommendation, very low certainty of evidence); maintaining a physical distance of at least 1 meter between people ("good practice statement"); and not sufficiently highlighting superiority of respirators (e.g. N95 masks) for general care - this particularly angered those who favor the aerosol, rather than droplet, mode of transmission for SARS-CoV-2. In general it seemed that the WHO panel carried over some details for infection control that do not have strong evidence for use and in some cases (plastic barriers) may be contradicted by other studies.

Note that much of the controversy involves how much weight to give transmission simulation studies - e.g. distances that SARS-CoV-2 travels under experimental conditions rather than real-world evidence which is much more difficult to come by. It's hard for an individual medical practice to make these decisions on their own, best to abide by state or local health department guidance.

Spring Covid Vaccination?

Canada released guidance for covid vaccination this spring, advocating for an additional dose of the XBB.1.5 vaccine recommended last fall. I'd look for the US to make similar recommendations soon. ACIP has a regular meeting scheduled February 28-29, but no agenda is yet available. FDA doesn't have anything scheduled, and they may not need a separate advisory committee meeting for this.

WRIS

In general we seem to be trending downward with our winter respiratory infections, but still lots of runny noses, coughs, and more around.

For RSV I still look primarily at hospitalization rates in young children, the purple line in the graph below, because I think it's the most accurate gauge of RSV. I suspect almost all of these hospitalized children are tested for RSV and flu. The rate clearly is trending down, it's looking like we won't replicate the horrible RSV season of last year.

Influenza-like illness seems to be cooling off as well, as seen in FLUView. Note this measurement includes respiratory illnesses mimicking flu so could be any respiratory virus; there are many more ways to look at flu activity in general, all with their own inaccuracies. In the past I have found this map to be representative of what I've seen clinically in my practice areas.

Covid wastewater (I've said before why I prefer this qualitative measurement) continues to trend downward, and levels are below that seen last year.

All told this is good news for those of you trying to manage your packed patient waiting rooms. Let's just hope you don't have a case of measles sitting in there somewhere!

Do You Even Know What a Broken Record Sounds Like?

I used this term when I said I was sounding like a broken record for repeating over and over my warnings about measles. I harp (pun intended) on this because measles is the most contagious infectious disease known and most younger clinicians in the US have never seen a case, meaning it can be missed easily. However, those same clinicians might never have heard a broken record either. Vinyl records made a bit of a comeback recently but even I no longer have a turntable to play vinyl records; I do have a few moldy vinyl albums from the 1960s and 70s. I'm occasionally tempted to purchase a good turntable, but I have no place for it and it's yet another diversionary rabbit hole I don't need. I ain't gonna call out the name vinyl around here.

Published on Leave a comment on Snow at Last

It was an exciting week for me. We had our first tangible amount of snow in 2 years. Last year, I paid big bucks (to me, but I'm a skinflint) to recondition my 30-year old snowblower that refused to start. However, it sat dormant through last winter, and I never tried it out to see if it actually worked. Happily, it performed well this week.

Most of the infectious disease newsworthiness still centers around covid and WRIS*, with one exception.

Oh Deer!

Like most other teen boys growing up in South Texas in the 1960s, I learned to hunt. Once I harangued my father to take me deer hunting, something he abhorred, but like the dutiful father he was he finally acquiesced. I shot a deer, clean kill instantly, but it was a terrible experience. The end of my hunting career. Still, I have no fondness for deer, especially the ones who eat my wife's painstakingly planted vegetation around the yard.

This new article gives me one more reason to despise deer. Investigators from various agencies in Michigan report 4 new cases of Mycobacterium bovis disease linked to deer exposure and include 3 older cases already reported. Of the 7 individuals, 3 were deer hunters, 1was a taxidermist, 1 handled a sick fawn, and 2 were immunocompromised, had no known animal contact, and had close contact with each other.

I found it most interesting that hunters may voluntarily submit deer heads for M. bovis testing in this part of Michigan since 1995. Since that time, 993 of 349,445 (about 0.3%) specimens have tested positive (and those hunters were advised to discard the venison from those animals). Deer-hunters and -lovers should take note.

Another Oral Covid Medication

Researchers in China reported results of a phase 2/3 randomized, double-blind, placebo controlled trial of a new protease inhibitor, simnotrelvir, combined with ritonavir, for treatment of mild to moderate covid illness in 1208 adults within 72 hours of symptom onset. The treatment group had significantly lessened time to sustained resolution of symptoms (180 hours vs. 216 hours) and decreased viral load on day 5 of treatment. Rebound was studied in a subset of subjects and was similar in the 2 groups.

We'll need to wait for further studies and FDA action to know whether this agent will become available in the US, but in general it's nice to have multiple options for covid management.

More Encouragement for Covid Vaccines

Two new studies added to the already large body of evidence confirming efficacy and safety of covid vaccines. First, a retrospective study using EMR data from multiple centers in the US showed lower rates of long covid in vaccinated children under 18 years of age: 4.5% in unvaccinated versus 0.7% in vaccinated, with some waning of protection over time. This is encouraging, but the study design itself is not optimal for measuring this type of effect. I'm waiting for prospective studies to give us a better handle on measuring this benefit.

Another group of investigators performed an extensive literature search to determine risks of various neuroimmunologic disorders, including Guillain-Barre syndrome, Bell palsy, myasthenia gravis, neuromyelitis optica spectrum disorders, multiple sclerosis and central demyelination, and myelin oligodendrocyte glycoprotein antibody-associated disease, following covid vaccination. This is a tough task since these illnesses exist at a low rate in the general population and mostly seem to be equally or more rare in vaccinated individuals.

The authors, after applying various quality methods to screen articles, ended up with 69 studies to include in the analysis. They present a ton of data, but distilling their remarks it does seem like the most evidence exists for an association between vaccination and GBS, especially for adenoviral vector vaccines but also for mRNA vaccines. Neither adenoviral nor SARS-CoV-2 natural infections have been convincingly linked to GBS so far, so this may be a true association. Bell palsy also showed a possible slight association following vaccination, but again these are exceedingly rare events. Worth the price of the article, or more since it is freely available, are the various discussions of limitations of these studies, compounded by the rarity of the conditions of interest. For example, individuals with mild GBS or Bell palsy may not seek medical attention, and this behavior might differ between vaccinated and unvaccinated persons. Other study problems such as publication bias, outcome reporting bias, and clinical heterogeneity also are mentioned by the investigators. I agree with the authors' conclusions that, given the unprecedented attention to covid vaccine safety, it is unlikely that rates of these rare conditions have been underestimated in vaccinated individuals, and vaccine benefits far outweigh any of these possible risks.

*WRIS

Winter Respiratory Infection Season plods along.

Influenza-like illness dropped a bit, uncertain if this will be sustained.

RSV hospitalizations continue to project downward:

Covid wastewater still hasn't approached levels of last winter; cases are down, but remember that case reporting methods have changed dramatically since last year and are more severely underreported now.

Overall a number of data sources suggest we may be turning the corner on WRIS, but still plenty of infections out there and definitely not too late for vaccination of eligible persons for any of these 3 pathogens.

One last note is a tip of the hat to Dr. Michael Schwartz, a frequent contributor to the Comments section of this blog. Last week he wrote "would you like to comment in your next post about California aligning COVID isolation recommendations with other respiratory illness ( most especially flu )? He referenced an order from the California Department of Public Health dated January 9. It specifically deals with covid and doesn't mention influenza directly and is mostly intended to redefine infectious periods for covid to conform with new data. It is short on references/links to source data. I was intrigued, however, to visit their mask advice page, and I think it's pretty helpful and might be useful to families who are confused about the different types of masks available.

In terms of Dr. Schwartz's request, he brings up an important practical point. In the midst of WRIS, much of the time we won't know which virus is causing a child's upper respiratory symptoms, and we need to use testing judiciously to inform treatment choices where indicated. Thus, it makes sense to have a general approach to URIs now. As any parent or pediatric healthcare provider knows, if you exclude every child from school every time they have a runny nose, our classrooms would be empty in the winter. However, in high risk circumstances such as contact with immunocompromised individuals, proper masking may help.

Also, I couldn't pass up sharing this facial hair guide for wearers of N95 and similar respirators:

So much for my plan to grow a wet noodle 'stache.

Snowy Times

Wallace Stevens wrote a famous poem called "The Snow Man," termed by one critic as the best short poem in the English language. I'm more drawn to his discussion of snow in "On the Way to the Bus." Unfortunately I can't find a copy of the latter poem freely available on the web and I would violate copyright laws by reproducing the complete piece here. So, I'll leave you with "The Snow Man," definitely not too shabby either.

One must have a mind of winter
To regard the frost and the boughs
Of the pine-trees crusted with snow;

And have been cold a long time
To behold the junipers shagged with ice,
The spruces rough in the distant glitter

Of the January sun; and not to think
Of any misery in the sound of the wind,
In the sound of a few leaves,

Which is the sound of the land
Full of the same wind
That is blowing in the same bare place

For the listener, who listens in the snow,
And, nothing himself, beholds
Nothing that is not there and the nothing that is.

Published on Leave a comment on What About Me?

This week I realized covid shares a characteristic with my granddaughter. Sometimes, when she is the only child in a room full of adults taking about endless banalities, she interrupts us with a "What about me?" plea. Every week I gather potential topics for this blog from key medical journal email alerts, feeds from a few selected sources like CIDRAP, scanning the Washington Post, New York Times, and Wall Street Journal dailies, watching national news broadcasts when I can, and just generally keeping my eyes and ears open. I must see dozens of potential topics to include next week, and I bookmark a subset to reconsider at the end of the week.

This week I had a few more topics than usual, around 20, that I needed to winnow down. I quickly realized that all but 1 of them were related to covid. Try as I might to include topics on general infectious diseases, covid has succeeded in becoming the center of attention this week. I'll do my best to summarize a few of the pearls.

Covid Vaccine Updates

Pediatric healthcare providers can rejoice in some more good news: according to the AAP, Moderna has joined Pfizer in allowing free returns of unused covid vaccine doses, making it less financially risky for practices to order vaccine.

A few new studies confirm high vaccine effectiveness extending into the omicron era. First, a cohort study in 4 Nordic countries looked at mRNA covid vaccine effectiveness in adolescents completing 2 vaccine doses between approximately April 2021 and April 2023. A little over 500,000 subjects were included. Vaccine effectiveness against hospitalization was 72.6% (95% CI 62.5-82.7) with a suggestion that heterologous dosing (1 Pfizer dose and 1 Moderna dose) had slightly higher effectiveness at 86.0% (56.8-100). Similar numbers were seen when just the omicron time period was analyzed at follow-up periods of 6 and 12 months. It's important to note that hospitalizations were relatively rare, regardless of vaccine status, as expected in an adolescent population. (Norway isn't included below because too few hospitalizations occurred to allow for analysis.)

Another study looked at VE in US children (5-11 yo) and adolescents (12-20 yo), the latter group in both delta and omicron periods and the former group only during the omicron period (no vaccine was available for the younger group during the delta wave). It looked at a "real world" population, i.e. not part of a formal research study but rather examining vaccine usage as implemented after authorization/approval, using data available from 7 pediatric healthcare organizations. Again VE was high, For the Pfizer vaccine during the delta time period, VE against infection was 98.4% with narrow CI (those were the good-old days at least in this one feature, no covid vaccine has great VE against infection nowadays). During the early omicron period (up through November 2022), VE against infection was 74% in the younger children and 82% in the adolescents; durability of the protection was fairly stable over a 10-month follow-up period, although the CIs became very wide because so few events occurred.

Finally I'll mention a study in the "elderly" because it contains very recent data. In Denmark, VE reported as hazard ratios of the XBB variant-based vaccine (the one in use starting last fall) was highly effective against hospitalization in this older age group. Note the very short follow-up period, this information clearly is very preliminary and could change significantly as time passes.

Covid Epidemiology

The more interesting information about covid epidemiology this week comes from abroad. First, I loved this study from the UK because it used smartphone tracing technology, preserving confidentiality, to identify important determinants of covid transmission. A key finding was that the probability of person-to-person transmission increased with time, first linearly at 1.1% per hour of exposure but extending for several days. Household exposures were most likely to result in transmission. Distance played a role of course, but longer exposures at greater distances had about equal risk of transmission as shorter exposures at shorter distances. I could spend an entire blog post and more on this article. This information can provide excellent guidance for quarantining and distancing in the event of a large covid wave in the future. Remember that the original guidance earlier in the pandemic for distancing of 6 feet was mostly a best guess to prevent transmission, no great data to guide that advice.

A report from the UK government summarizes a wealth of data as the following (see page 3 of the pdf in the link):

"... COVID-19 Omicron variant cases were most infectious around symptom onset and up to 5 days after, but could potentially be infectious for longer, especially for cases that are hospitalised, immunocompromised, or otherwise high risk. Three studies looked at transmission before symptom onset. These suggested that between a third and a half of transmission events occurred before symptom onset in the index case. However, while some studies included substantial numbers of cases, most studies included relatively few cases, and the majority of studies included cases with Omicron variant BA.1 and BA.2, with only a small number of studies reporting evidence from 2023."

This information can help inform your discussions with all those parents who wonder about transmission to high risk family members and whether to risk exposure for a special event. If you want more data than you (or I) can handle about what's going on in the UK with covid, see this link. The Excel files are massive but very interesting for those of you who want to take a deep dive.

The final mention of epidemiology is a source for concern and caution. The Pan American Health Organization, PAHO, that is the branch of the WHO overseeing public health in the Americas, reported on respiratory illness activity in the southern hemisphere which is now in summer season. The key take-home point here is that, although North American is driving a lot of the SARS-CoV-2 positivity now, there is significant covid illness in Central and South America. This implies that covid is not quite a winter respiratory virus, at least not yet.

Covid Bottom Lines

As we enter our 4th year of covid, I realized I've learned a few key lessons to be applied for the future:

  • It's difficult to compare illness rates and other outcomes in the US over the years, primarily because we aren't collecting information in the same way as we did early in the pandemic. Wastewater data are mostly obtained as they were before, but this is at best a qualitative data source.
  • Covid vaccines are the most closely studied and monitored in history with now over 5 billion people worldwide receiving at least one dose. Every credible study/report has confirmed that, regardless of age or underlying risk factors, vaccinated individuals will have better outcomes than being unaccinated and infected, even after being infected multiple times. This takes into account all adverse events following vaccination itself. For virtually every individual, vaccination is the better choice. From a public health perspective, vaccination of some low risk groups may not be cost effective. This is why the UK, for example, does not provide vaccine for some healthy children; UK health authorities have decided the money is better spent on other aspects of health care.
  • Although there are similarities, SARS-CoV-2 is not just like influenza virus. The mutation rate is much higher, meaning that we still face a faster moving target for new vaccine and therapeutic drug development. Also, as mentioned above, seasonality isn't yet clear. So far SARS-CoV-2 isn't just a winter respiratory virus.
  • Even though the omicron era seems to have brought less disease severity, SARS-CoV-2 is still a major killer, now at a rate of about 1500 deaths per week.

Please encourage everyone to be up-to-date on covid and all other vaccines.

WRIS

Winter Respiratory Infection Season clearly is still with us. I await more data to see if the winter school break resulted in fewer, greater, or had no effect on WRIS infection numbers. However, I did notice a report from China that provided evidence that school breaks lessened influenza transmission during the years 2015-2018.

RSV-NET: CDC is still projecting a downturn nationally, but too early to be certain of this.

FluView still shows significant influenza-like illness activity, at least as of a week ago. It's definitely not too late to be vaccinated.

And ... More What About Me

It's my blog, what could be a more pitiful plea for attention? So, speaking of me, note that the CDC published the 2024 adult immunization guide that not only includes old codgers such as yours truly but also extends down to 19 years of age.

One last bit, an update to my bird feeder adventures I mentioned last week. I had a great few days of multiple bird species sightings, followed by a squirrel invasion - those dastardly rodents cleaned out the birdseed supply in a couple days. I've now been researching squirrel deterrents, being careful to not actually hurt them although I admit to having occasional sciuricidal thoughts. It looks like I'll be moving the feeder and engaging in some high-wire techniques to squirrel-proof the new location, hoping I don't end up with a spectacular ladder fall and resultant visit to my local ER.

Published on Leave a comment on Winter Distractions

My soon-to-be daughter-in-law recently gave me a bird feeder - not just any bird feeder, but a smart one that has a camera connected to my wifi that takes photos and videos of any birds that show up. I had my first visitors this morning, a few days after I stocked it with birdseed.

In the meantime, winter is here.

WRIS

A lot going on with our Winter Respiratory Infection Season, including some new items.

CDC issued new (or actually old) guidance for use of the long-acting monoclonal antibody nirsevimab for preventing RSV infection in young infants. The change was prompted by the announcement of greater availability of nirsevimab because the manufacturer released an additional 230,000 doses this month. Previously the guidance had indicated that the product should be prioritized for just a subset of infants at higher risk, but now recommendations are to go back to the original plan to administer to all infants less than 8 months of age as well as to infants 8-19 months of age with high risk conditions:

  • Children who have chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season
  • Children with severe immunocompromise
  • Children with cystic fibrosis who have severe disease
  • American Indian and Alaska Native children

If supply is still limited in your particular area, then prioritization should be used as before. Still a bit vague but very important are all the nuances for ordering, administering, and being reimbursed for the product.

Along that same line, RSV may have peaked nationally.

Even with some good news about RSV slowing down, there's still plenty to go around. Also, influenza continues to drive a lot of healthcare usage for all ages around the country. Here is the percentage of emergency department visits due to the various respiratory infections:

Be aware that this site allows you to look just at your local jurisdiction - here is Maryland:

Covid

This week covid deserves a separate heading with a few new twists. Wastewater tracking once again has accurately predicted a surge in infections.

The JN.1 variant has increased rapidly and is projected to be the predominant covid strain in the US, but without any indication (yet) that it has increased virulence.

This might be a good time to review a bit about variants and also some recent covid findings. Variant nomenclature is confusing to me, I can only imagine how the general public sees this. Here is an evolutionary tree from the same CDC weblink as above.

The nomenclature is from the Pango system, but most people are more familiar with the WHO classification: the delta variant (remember those horrible days?) is B.1.617.2 near the left of the diagram. Omicron is represented in both BA.1 and BA.2. Now here's the important part when we consider new variants, immune-escape, and vaccines: JN.1 has developed on the BA.2 side, just like XBB but on a different branch of the tree. Remember that our current vaccines are based on XBB. As I've mentioned previously, XBB vaccine antibody seems to neutralize JN.1 pretty well in the test tube, but all vaccine (and natural infection) immunity declines significantly within a few months after vaccination or immunization. I would still expect the current vaccine to be pretty good for protecting against severe disease with JN.1 infection.

Although near and dear to my heart, I don't usually talk about old folks in this blog. However, a study of old folks in the Netherlands lends support to the idea that current vaccines are effective against new variants. Without going into details, you can see this study has very recent data and show excellent effectiveness for hospitalization and ICU admission for old folks. It's likely this benefit translates to the younger population that of course has lower rates of hospitalization overall.

Another recent study sheds some light on a question I've been wondering about for some time, namely how common asymptomatic covid infection might be in the omicron era. You might recall that one of the early surprises in 2020 was that asymptomatic infection was both common and very important for viral spread. That made the pandemic much more difficult to control. Now we have data from Hong Kong where rather unique epidemiologic circumstances prevailed. With a population of 7.5 million, Hong Kong officials had still had managed to prevent covid spread very effectively prior to the omicron era, with only about 0.5% of the population having been infected. That ended in early 2022, but it also offered researchers an opportunity to look at rates of asymptomatic infection during the omicron period because virtually none of the population had been infected previously. Using antibody testing, they estimated that 16% of the population was infected during the first 6 months of 2022 and that the percentage of asymptomatic cases was at least 42% (taken from those with reported SARS-CoV-2 infections) and possibly as high as 72% (looking at combined reported and unreported infections). Wow. That doesn't necessarily mean we would have those same rates of asymptomatic infection in the US where we've had a very different epidemiologic curve over the years, but I think it's likely we have a lot of asymptomatic covid surrounding us now.

Some good news about long covid, AKA PCC (post-COVID-19 condition) in children. This Canadian study looked at pediatric emergency department data and found that PCC was present in only 0.67% at the12-month follow-up periods in children testing positive for SARS-CoV-2. That's not the only good news part of this; the rate in a control group of children testing negative for covid was 0.16%, suggesting once again that other infections can trigger some of these long term symptoms. We have NIH-funded studies in the US ongoing now, with good control groups, that should go a long way in giving us guidance for managing PCC as well as other long-term conditions triggered by infections.

The Tipping Point

FDA officials, including Peter Marks who is the director of CBER, recently published a viewpoint article about a vaccination tipping point, i.e. the fact that vaccine hesitancy issues have resulted in a severe decrease in immunization coverage, opening us up to major outbreaks soon. I mention this both because it perfectly supports my views expressed in recent weeks but also it gives me a chance to give credit where credit is due. The term "tipping point," as applied here, often has been credited to Malcolm Gladwell. However, his popularization of the term in a sociologic context earlier this century should go to Morton Grodzins who first adapted this for use in explaining racial integration of neighborhoods in the middle of the 20th century. I'm hoping Gladwell credited him.

In Case You Missed These

Two other articles caught my eye this past week. First is a quality improvement article about shortening treatment duration for children with community acquired pneumonia and skin and soft tissue infections. If you're one of those practitioners who still treats these for 10 days (because we have 10 fingers), check it out.

Secondly, I was attracted to a report about variation in rates of how primary pediatric providers use pediatric subspecialty consultations. Although not the main focus of the report, I was most drawn to the mention that the top 2 conditions for using a pediatric infectious diseases specialist were positive tuberculin skin test and inactive tuberculosis. This jives with my personal experience and certainly points to opportunities to lessen use of subspecialty health care. Multiple resources exist for managing latent tuberculosis infection, including the AAP's Red Book, the CDC, and UCSF's Pediatric TB Resource Page.

For the Birds

My first video stars at the bird feeder were a white-breasted nuthatch, maybe a tufted titmouse (looks a lot like the nuthatch, I couldn't figure it out), and a house finch. When I received the bird feeder, I immediately wondered how best to avoid attracting squirrels and other rodents. I did a bit of web searching and then journeyed to my local bird authorities at the Woodend Nature Sanctuary who of course turned out to be the most helpful. I armed my feeder with capsaicin-treated safflower seeds, not a favorite of squirrels and the like, plus birds can't taste the hot pepper. So far the birds seem to like it.

As for me, it appears I've fallen down another rabbit hole, similar to my butterfly fascination. My wanderings have now included a look at how climate change is affecting our bird populations, as projected by the Audubon Society (apologies for using his name, now controversial, but the Society hasn't yet changed it) in their field guide.

Here is how things will change for the white-breasted nuthatch's winter range with a 1.5 C increase in temperature.

For the tufted titmouse

and the house finch

With more severe temperature increases, the ranges are altered more dramatically. I still hope for some action that will reverse these trends.

Unless otherwise indicated, the content and opinions expressed on this web site are those of the author(s). They are not endorsed by and do not necessarily reflect the views of the George Washington University.
Viewing Message: 1 of 1.
 Notice

This site uses cookies to offer you a better browsing experience. Visit GW’s Website Privacy Notice to learn more about how GW uses cookies.